CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer

Gerard M Walls, Jamie B Oughton, Anthony J Chalmers, Sarah Brown, Fiona Collinson, Martin D Forster, Kevin N Franks, Alexandra Gilbert, Gerard G Hanna, Nicola Hannaway, Stephen Harrow, Tom Haswell, Crispin T Hiley, Samantha Hinsley, Matthew Krebs, Geraldine Murden, Rachel Phillip, Anderson J Ryan, Ahmed Salem, David Sebag-MontefoirePaul Shaw, Chris J Twelves, Katrina Walker, Robin J Young, Corinne Faivre-Finn, Alastair Greystoke

Research output: Contribution to journalArticle

12 Downloads (Pure)

Abstract

Lung cancer is the leading cause of cancer mortality worldwide and most patients are unsuitable for 'gold standard' treatment, which is concurrent chemoradiotherapy. CONCORDE is a platform study seeking to establish the toxicity profiles of multiple novel radiosensitisers targeting DNA repair proteins in patients treated with sequential chemoradiotherapy. Time-to-event continual reassessment will facilitate efficient dose-finding.

Original languageEnglish
Pages (from-to)61-66
Number of pages6
JournalClinical and translational radiation oncology
Volume25
Early online date22 Sep 2020
DOIs
Publication statusEarly online date - 22 Sep 2020

Bibliographical note

© 2020 The Authors. Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology.

Fingerprint Dive into the research topics of 'CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer'. Together they form a unique fingerprint.

Cite this